Recent Advances in the Clinical Outcome of Chronic Hepatitis B Patients
A special issue of Livers (ISSN 2673-4389).
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 2207
Special Issue Editor
Interests: HBV infection; hepatocellular carcinoma; clinical immunology; cirrhosis; natural killer cells; discontinuation of nucleos(t)ide analogues
Special Issue Information
Dear Colleagues,
During the past several decades we have witnessed major progress in all areas of hepatitis B virus (HBV) biology, including replication, pathobiology and antiviral therapy. Investigations on viral DNA replication have uncovered covalently closed circular DNA (cccDNA) amplification as the mechanism for HBV persistence. Studies in animal models have demonstrated that viral clearance is associated with a strong cytotoxic T-cell response that can destroy infected hepatocytes. Nucleos(t)ide analogues block viral replication, but they cannot cure chronic HBV infections and prevent the development of hepatocellular carcinoma.
The ultimate goals of this Special Issue are not only to obtain a more precise understanding of the HBV life cycle, but also to acquire an understanding that will lead to more effective treatments and pathogenic process. Furthermore, another ambitious aim of this Issue is to explore the significant clinical role of HBV infection in relevance with the current public health problems and new medical needs.
Best regards,
Dr. Hariklia Kranidioti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HBV pathogenesis
- antivirals
- new antiviral targets
- adaptive and innate immunity in HBV infection
- hepatitis delta virus
- hepatocellular carcinoma
- extrahepatic manifestations
